Vesicoureteral reflux: a new treatment algorithm.
Vesicoureteral reflux (VUR) affects about 1% of all children and carries an increased risk of pyelonephritis and long-term renal impairment. There are several approaches to the treatment of VUR: antibiotic prophylaxis (conservative treatment), open surgery, and endoscopic treatment. For many patients, endoscopic treatment cures VUR with a single procedure, eliminating the need for long-term antibiotic treatment and avoiding the trauma of a major surgical procedure. The choice of material for endoscopic treatment is of key importance, and, until recently, all available materials were associated with concerns regarding safety and efficacy. Emerging data demonstrate that dextranomer/hyaluronic acid (Dx/HA) copolymer has good long-term safety and efficacy in treating VUR. A new treatment algorithm is, therefore, proposed, recommending that most children with persistent VUR (longer than 1 year) be offered endoscopic treatment with Dx/HA copolymer as an alternative to prolonged antibiotic prophylaxis or open surgery.
Stenberg
Arne
A
Section of Urology, University Children's Hospital, S-75185 Uppsala, Sweden.
Hensle
Terry W
TW
Läckgren
Göran
G
D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D003558:Cystoscopy; D006801:Humans; D013520:Urologic Surgical Procedures; D014718:Vesico-Ureteral Reflux / Q000628:therapy*
D000900:Anti-Bacterial Agents